Signalchem Lifesciences Corporation
Richmond, Canada
|
Signalchem Lifesciences Corporation is a clinical-stage company developing novel targeted therapies for oncology. SLC has a strong small-molecule drug development pipeline. The company's product SLC-391 is a highly selective small molecule AXL inhibitor with desirable potency and pharmaceutical properties. It is highly potent with a single-digit nanomolar IC50.